Literature DB >> 1364845

Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat.

M A Barrand1, B A Callingham, P Dobbin, R C Hider.   

Abstract

1. The fate and disposition of [59Fe]-ferric [3H]-maltol after intravenous administration were investigated in anaesthetized rats. Immediate dissociation of ferric iron from maltol took place in the circulation even with high doses of ferric maltol (containing 1 mg elemental iron). In plasma samples withdrawn within 1 min of injection and subjected to gel filtration, 59Fe eluted with the high molecular weight proteins whilst the tritium was associated with low molecular weight material. 2. The rates of elimination of 59Fe and of tritium from the plasma and their ultimate fate were very different. The half life for 59Fe in the plasma was around 70 min and 59Fe appeared mainly in the bone marrow and liver. There was an initial rapid exit of tritium from the plasma with a half life of around 12 min. This was followed either by a plateau or by a rise in tritium levels, involving entry of maltol metabolites into the circulation. These metabolites could be recovered in the urine. 3. Entry of 59Fe and of tritium into the blood plasma after intraduodenal administration of [59Fe]-ferric [3H]-maltol was also very different. At low doses of ferric maltol (containing 100 micrograms elemental iron), the tritium appeared in the plasma in highest amounts within seconds and then decreased whilst there was a slow rise in 59Fe levels. At higher doses of ferric maltol (containing 7 mg elemental iron), levels of 59Fe in the plasma were highest at 5 min and then fell whereas tritium levels rose steadily. Mucosal processing of 59Fe prevented further entry of iron at high dose into the circulation. 4. Initial rates of uptake of [3H]-maltol into isolatcd intestinal fragments were measured over a range of concentrations and revealed that maltol alone could diffuse freely into the tissues whereas maltol complexed to iron showed saturable uptake kinetics similar to those seen with the iron itself. 5. After intestinal uptake, 59Fe and tritium were associated with different subcellular fractions, maltol itself being metabolized to the glucuronide conjugate within the intestinal mucosa. 6. It is concluded that dissociation of metal and ligand takes place before entry into the intestinal mucosa. Iron is then taken up on the endogenous carrier and processed in the normal way whilst maltol enters by diffusion, its rate of entry being limited by the degree of dissociation. It is subsequently metabolized by conjugation and eliminated rapidly from the body in the urine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1364845      PMCID: PMC1917947          DOI: 10.1111/j.1476-5381.1991.tb12240.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Gastrointestinal effects of acute ferrous sulfate poisoning in rats.

Authors:  S G Nayfield; T H Kent; N F Rodman
Journal:  Arch Pathol Lab Med       Date:  1976-06       Impact factor: 5.534

2.  Hydroxyl radicals and the toxicity of oral iron.

Authors:  A Slivka; J Kang; G Cohen
Journal:  Biochem Pharmacol       Date:  1986-02-15       Impact factor: 5.858

3.  Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy.

Authors:  M Grootveld; J D Bell; B Halliwell; O I Aruoma; A Bomford; P J Sadler
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

Review 4.  Mechanisms and regulation of intestinal iron absorption.

Authors:  T J Peters; K B Raja; R J Simpson; S Snape
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.

Authors:  P Brissot; T L Wright; W L Ma; R A Weisiger
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol.

Authors:  J A Levey; M A Barrand; B A Callingham; R C Hider
Journal:  Biochem Pharmacol       Date:  1988-05-15       Impact factor: 5.858

7.  Interactions of pH and ascorbate in intestinal iron absorption.

Authors:  D M Hungerford; M C Linder
Journal:  J Nutr       Date:  1983-12       Impact factor: 4.798

8.  Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine.

Authors:  M A Barrand; B A Callingham; R C Hider
Journal:  J Pharm Pharmacol       Date:  1987-03       Impact factor: 3.765

9.  The importance of reductive mechanisms for intestinal uptake of iron from ferric maltol and ferric nitrilotriacetic acid (NTA).

Authors:  M A Barrand; R C Hider; B A Callingham
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

10.  Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate.

Authors:  R K Singh; M A Barrand
Journal:  J Pharm Pharmacol       Date:  1990-04       Impact factor: 3.765

View more
  8 in total

1.  Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Authors:  Bernd Bokemeyer; Annette Krummenerl; Christian Maaser; Stefanie Howaldt; Michael Mroß; Nick Mallard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

3.  Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Authors:  C Schmidt; T Ahmad; Z Tulassay; D C Baumgart; B Bokemeyer; S Howaldt; A Stallmach; C Büning
Journal:  Aliment Pharmacol Ther       Date:  2016-05-29       Impact factor: 8.171

Review 4.  Diagnosis and treatment of anemia in patients with inflammatory bowel disease.

Authors:  Victoria Mücke; Marcus M Mücke; Tim Raine; Dominik Bettenworth
Journal:  Ann Gastroenterol       Date:  2016-09-06

Review 5.  Iron deficiency anaemia: pathophysiology, assessment, practical management.

Authors:  Aditi Kumar; Esha Sharma; Alexandra Marley; Mark A Samaan; Matthew James Brookes
Journal:  BMJ Open Gastroenterol       Date:  2022-01

Review 6.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

7.  Oral Ferric Maltol Does Not Adversely Affect the Intestinal Microbiome of Patients or Mice, But Ferrous Sulphate Does.

Authors:  Awad Mahalhal; Alessandra Frau; Michael D Burkitt; Umer Z Ijaz; Christopher A Lamb; John C Mansfield; Stephen Lewis; D Mark Pritchard; Chris S Probert
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

8.  Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Authors:  Stefanie Howaldt; Eugeni Domènech; Nicholas Martinez; Carsten Schmidt; Bernd Bokemeyer
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.